vorinostat and Benign Neoplasms studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Research Excerpts

Excerpt	Relevance	Reference
" Suberoylanilidehydroxamic acid (SAHA=vorinostat) is the most clinical advanced compound of the class and was approved by the US FDA in October 2006 for the treatment of refractory cutaneous T-cell lymphoma."	9.16	Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma or leukemia. ( Abel, U; Deubzer, HE; Eisenmenger, A; Karapanagiotou-Schenkel, I; Kulozik, A; Milde, T; Oehme, I; Witt, O; Witt, R, 2012)
" Suberoylanilidehydroxamic acid (SAHA=vorinostat) is the most clinical advanced compound of the class and was approved by the US FDA in October 2006 for the treatment of refractory cutaneous T-cell lymphoma."	5.16	Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma or leukemia. ( Abel, U; Deubzer, HE; Eisenmenger, A; Karapanagiotou-Schenkel, I; Kulozik, A; Milde, T; Oehme, I; Witt, O; Witt, R, 2012)
" Vorinostat and romidepsin have been approved for treating cutaneous T-cell lymphoma in patients with progressive, persistent or recurrent disease."	4.88	HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. ( Khan, O; La Thangue, NB, 2012)
" The hydroxamic acid derivative SAHA (also known as vorinostat or Zolinza®) and the cyclic depsipeptide FK228 (romidepsin or Istodax®) have gained approval from the US FDA for the treatment of cutaneous T-cell lymphoma."	4.88	Current trends in the development of histone deacetylase inhibitors: a review of recent patent applications. ( Thaler, F, 2012)
"Preliminary anticancer activity was observed in patients with refractory Hodgkin lymphoma, perivascular epithelioid tumor, and hepatocellular carcinoma."	2.82	Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. ( Falchook, GS; Fanale, MA; Fu, S; Garrido-Laguna, I; Hong, DS; Janku, F; Kaseb, AO; Kurzrock, R; Meric-Bernstam, F; Naing, A; Park, H; Patel, S; Piha-Paul, SA; Subbiah, V; Tsimberidou, AM; Velez-Bravo, VM; Wheler, JJ; Zinner, RG, 2016)
"Patients with advanced solid tumors (n = 78) were enrolled following a 3 + 3 design, with dose expansion for those with responsive tumors."	2.80	Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. ( Araujo, D; Fu, S; Hess, K; Hong, D; Hou, MM; Hwu, P; Janku, F; Karp, D; Kee, B; Kurzrock, R; Meric-Bernstam, F; Naing, A; Piha-Paul, S; Subbiah, V; Tsimberidou, A; Wheler, J; Wolff, R; Zinner, R, 2015)
" DLTs in the intermittent dosing scheduled included thrombocytopenia and fatigue."	2.79	A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors. ( Alberti, D; Ames, MM; Bailey, HH; Deming, DA; Eickhoff, J; Espinoza-Delgado, I; Kolesar, JM; Marnocha, R; McGovern, RM; Ninan, J; Reid, JM; Schelman, WR; Wilding, G; Wright, J, 2014)
" Patients were treated orally with escalating doses of HCQ daily (QD) (d 2 to 21 of a 21-d cycle) in combination with 400 mg VOR QD (d one to 21)."	2.79	Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors. ( Amaravadi, RK; Carew, JS; Curiel, TJ; Davis, LE; Espitia, CM; Giles, FJ; Mahalingam, D; Mita, AC; Mita, M; Nawrocki, ST; Sarantopoulos, J; Wood, L, 2014)
"Vorinostat is a small molecule inhibitor of class I and II histone deacetylase enzymes which alters the expression of target genes including the cell cycle gene p21, leading to cell cycle arrest and apoptosis."	2.78	Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes. ( Alberti, D; Bailey, HH; Espinoza-Delgado, I; Hoang, T; Holen, KD; Kim, K; Kolesar, JM; Schelman, WR; Seo, S; Traynor, AM; Wilding, G; Wright, JJ, 2013)
"Bortezomib dosing was increased using a standard phase I dose-escalation schema."	2.78	A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies. ( Alberti, D; Ames, MM; Attia, S; Bailey, HH; Eickhoff, J; Espinoza-Delgado, I; Hoang, T; Holen, KD; Jiang, Z; Kolesar, JM; Marnocha, R; McGovern, RM; Reid, JM; Schelman, WR; Traynor, AM; Wilding, G; Wright, JJ, 2013)
"Oral vorinostat was administered on days 1-5 and 8-12 of a 21-day cycle (starting dose 180 mg/m(2) /day with dose escalations to 230 and 300 mg/m(2) /day)."	2.78	A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916). ( Ahern, CH; Ames, MM; Blaney, SM; Espinoza-Delgado, I; Horton, TM; Ingle, AM; McGovern, RM; Muscal, JA; Reid, JM; Thompson, PA; Weigel, BJ, 2013)
"Patients with advanced solid tumors or non-Hodgkin's lymphomas were eligible."	2.76	Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas. ( Chen, EX; Egorin, MJ; Espinoza-Delgado, I; Hirte, HW; Holleran, JL; Hotte, SJ; Laughlin, A; McGill, S; Moretto, P; Oza, AM; Siu, LL; Stathis, A; Stayner, LA; Wang, L; Webster, S; Zhang, WJ, 2011)
"Mean vorinostat plasma AUC was higher than reported previously at a similar dose when used as single agent or in combination with other cytotoxics."	2.76	Unexpected high levels of vorinostat when combined with vinorelbine in patients with advanced cancer. ( Arellano, C; Campone, M; Chalret du Rieu, Q; Chatelut, E; Delord, JP; Filleron, T; Gandia, P; Hennebelle, I; Lochon, I; Pierga, JY; Poublanc, M, 2011)
" V concentrations higher than previously reported with oral dosing were achieved."	2.76	A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors. ( Ames, MM; Cane, LM; Carvajal, RD; Dials, HJ; Dickson, MA; Gonen, M; Grant, S; Lefkowitz, RA; McGovern, RM; Rathkopf, DE; Reid, JM; Roberts, JD; Schwartz, GK, 2011)
" One week later, daily vorinostat dosing was begun and continued until toxicity or disease progression occurred."	2.75	Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. ( Belani, CP; Beumer, JH; Egorin, MJ; Harvey, RD; Holleran, J; Ivy, SP; Kummar, S; Lin, Y; LoRusso, P; Ramalingam, SS; Sarantopoulos, J; Shibata, S; Yerk, M, 2010)
" Pharmacokinetic studies were performed with the initial dose."	2.75	Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report. ( Adamson, PC; Ames, MM; Blaney, SM; Fouladi, M; Gilbertson, RJ; Ingle, AM; Park, JR; Reid, JM; Schaiquevich, P; Speights, R; Stewart, CF; Sun, J; Zwiebel, J, 2010)
"A dedicated QTc study in advanced cancer patients is a robust means for assessing risk for ventricular repolarization prolongation."	2.74	A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancer. ( Chodakewitz, JA; Comisar, W; Friedman, E; Iwamoto, M; Li, X; Munster, PN; Patterson, JK; Rubin, EH; Van Belle, S; Van Dyck, K; Wagner, JA, 2009)
"In total, 32 patients were treated; vorinostat was dosed at 400, 600, 800, or 1000 mg day(-1) on days 1-3, followed by doxorubicin (20 mg m(-2)) on day 3 for 3 of 4 weeks."	2.74	Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. ( Chiappori, A; Daud, A; Egorin, M; Lee, JH; Marchion, D; Minton, S; Munster, PN; Simon, G; Springett, G; Sullivan, D; Thomas, S, 2009)
" Once-daily dosing was tested at 400 and 500 mg."	2.74	Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors. ( Fujiwara, Y; Hardwick, JS; Iwasa, T; Kanazu, S; Otsuki, T; Tamura, T; Yamada, K; Yamada, Y; Yamamoto, N, 2009)
"Both schedules of vorinostat (400 mg oral qd x 14 days or 300 mg bd x 7 days) were tolerated well in combination with carboplatin (area under the concentration versus time curve = 6 mg/mL x min) and paclitaxel (200 mg/m(2))."	2.73	Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. ( Argiris, AE; Belani, CP; Egorin, MJ; Lagattuta, TF; Musguire, LA; Parise, RA; Potter, DM; Ramalingam, SS; Ramananthan, RK; Ramanathan, RK; Stoller, RG; Zwiebel, JA, 2007)
"Mainly sight saw in cancer chemotherapeutics, HDAC inhibitors have also found a promising role in other diseases (neurodegenerative disorders, cardiovascular diseases, and viral infections) and successfully entered in various combination therapies (pre-clinical/clinical stages)."	2.72	Paradigm shift of "classical" HDAC inhibitors to "hybrid" HDAC inhibitors in therapeutic interventions. ( Chatterjee, DR; Contractor, D; Jain, A; Kumar, D; Nagpure, M; Rana, P; Satpute, DP; Vaidya, GN; Venkatesh, A, 2021)
"Cancer has been the second heath killer being next only to cardiovascular diseases in human society."	2.72	2-Aminothiazole: A privileged scaffold for the discovery of anti-cancer agents. ( Gao, H; Long, J; Tang, Z; Wan, Y, 2021)
"Patients (n = 23) received single doses of 400 mg vorinostat on day 1 (fasted) and day 5 (fed) with 48 hours of pharmacokinetic sampling on both days."	2.72	A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer. ( Agrawal, NG; Du, L; Frankel, SR; Friedman, EJ; Gottesdiener, KM; Iwamoto, M; Mazina, KE; Ricker, JL; Rubin, EH; Scott, P; Sun, L; Wagner, JA, 2006)
" The maximum tolerated dose was 400 mg qd and 200 mg bid for continuous daily dosing and 300 mg bid for 3 consecutive days per week dosing."	2.71	Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. ( Chiao, JH; Chu, E; Curley, T; Heaney, M; Kelly, WK; Krug, LM; MacGregore-Cortelli, B; Marks, PA; O'Connor, OA; Olgac, S; Richardson, S; Richon, VM; Scher, H; Schwartz, L; Secrist, JP; Tong, W, 2005)
"The global pandemic of drug-sensitive cancers and the increasing threat from drug-resistant cancers make an urgent need to develop more effective anti-cancer candidates."	2.61	Quinolone hybrids and their anti-cancer activities: An overview. ( Gao, F; Wang, T; Xiao, J; Zhang, X, 2019)
"Anticancer agents are critical for the cancer treatment, but side effects and the drug resistance associated with the currently used anticancer agents create an urgent need to explore novel drugs with low side effects and high efficacy."	2.61	1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships. ( Liu, Y; Xu, Z; Zhao, SJ, 2019)
"Currently, four gene therapeutics, two cancer vaccines with genetic bases, and seven epigenetic medications are available for cancer treatment."	2.55	Novel treatment opportunities for sulfur mustard-related cancers: genetic and epigenetic perspectives. ( Abdollahi, M; Rahmani, S, 2017)
"Vorinostat is a histone deacetylase inhibitor that has demonstrated preclinical activity in numerous cancer models."	2.49	Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor. ( Agrawal, NG; Friedman, EJ; Iwamoto, M; Rubin, EH; Sandhu, P; Wagner, JA, 2013)
"Vorinostat was approved in the United States in 2006 for the treatment of cutaneous manifestations of T-cell lymphoma in patients with progressive, persistent, or recurrent disease on or following 2 systemic therapies."	2.46	The role of histone deacetylase inhibitors in the treatment of patients with cutaneous T-cell lymphoma. ( Hymes, KB, 2010)
"Vorinostat is a potent histone deacetylase inhibitor that blocks the catalytic site of these enzymes."	2.45	Development of vorinostat: current applications and future perspectives for cancer therapy. ( Garcia-Vargas, J; Hardwick, JS; Richon, VM, 2009)
"Applying light to control tumors' genetic behavior directly was still a challenge so far."	1.48	Light-Trigerred Cellular Epigenetic Molecule Release To Reverse Tumor Multidrug Resistance. ( Guan, Q; Jin, X; Shi, L; Xu, L; Yang, J; Zhu, X, 2018)
"The anticancer effects of histone deacetylase inhibitors (HDACi) vary between patients, and their molecular mechanisms remain poorly understood."	1.48	HSP72 functionally inhibits the anti-neoplastic effects of HDAC inhibitors. ( Fujii, K; Idogawa, M; Iwatsuki, K; Jimura, N; Kanekura, T; Kondo, T; Suzuki, N, 2018)
"Cisplatin is a widely used anticancer drug in clinic."	1.46	Supramolecular cisplatin-vorinostat nanodrug for overcoming drug resistance in cancer synergistic therapy. ( Huang, W; Xu, S; Yan, D; Zhou, Y; Zhu, X, 2017)
" Consistent additive to synergistic interactions were observed in HCT116 cells when PENT was combined with SAHA at all drug tested concentrations."	1.46	Enhanced anticancer efficacy of histone deacetyl inhibitor, suberoylanilide hydroxamic acid, in combination with a phosphodiesterase inhibitor, pentoxifylline, in human cancer cell lines and in-vivo tumor xenografts. ( Chandrasekhar, KB; Karthikeyan, K; Khan, FR; Kulkarni, NM; Narayanan, S; Nidhyanandan, S; Raghul, J; Reddy, ND; Thippeswamy, BS; Vijaykanth, G, 2017)
"We recorded a total of 31 adverse events (26 grade 1 and five grade 2) in all study participants (n = 20)."	1.46	No adverse safety or virological changes 2 years following vorinostat in HIV-infected individuals on antiretroviral therapy. ( Dantanarayana, A; Elliott, JH; Hagenauer, M; Hoy, JF; Lewin, SR; McMahon, J; Mota, TM; Prince, HM; Purcell, DFJ; Rasmussen, TA; Rhodes, A; Roney, J; Spelman, T; Tennakoon, S; Wightman, F, 2017)
" 23bb has a good pharmacokinetic profile with oral bioavailability of 47."	1.43	Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer. ( Cao, D; Chen, L; Chen, X; Liu, Z; Long, C; Ma, L; Niu, T; Tang, M; Wang, F; Wang, T; Wang, X; Xiang, W; Yang, Z; Yi, Y; You, J, 2016)
"In breast cancer patients, methylation of the SOX11 promoter was shown to correlate with estrogen receptor status, suggesting that SOX11 may be functionally re-expressed during treatment with HDAC inhibitors in specific patient subgroups."	1.42	DNA methylation and histone modifications regulate SOX11 expression in lymphoid and solid cancer cells. ( Andersson, E; Ek, S; Guldberg, P; Gustavsson, E; Holm, K; Kuci, V; Nordström, L; Ringnér, M, 2015)
"Because many cancers have acquired mutations in DNA damage checkpoints or repair pathways, we hypothesized that these cancers may be susceptible to treatments that target compensatory pathways."	1.40	Histone deacetylase inhibitors selectively target homology dependent DNA repair defective cells and elevate non-homologous endjoining activity. ( Choi, K; Choi, Y; Fox, J; Hendrickson, EA; Kim, S; Li, L; Mejia, M; Muller, M; Myung, K; Oh, S; Ruangpradit, W; Saberi, A; Smith, S; Takeda, S; Wang, Y, 2014)
"To investigate their potential use as cancer testis antigen (CTA) vaccines, we studied the expression of 12 cancer testis (CT) genes in 20 LCL by RT-PCR."	1.39	EBV-transformed lymphoblastoid cell lines as vaccines against cancer testis antigen-positive tumors. ( Held, G; Kaddu-Mulindwa, D; Kubuschok, B; Neumann, F; Pfreundschuh, M; Preuss, KD; Roemer, K; Widmann, T; Zwick, C, 2013)
"Therefore, we explored whether the anticancer activity of nutlin-3 could be enhanced by combination with histone deacetylase inhibitors (HDACi), i."	1.38	Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression. ( Beck, JF; Palani, CD; Sonnemann, J, 2012)
"Several cancers, however, fail to respond to TRAIL's antineoplastic effects."	1.38	Histone deacetylase inhibitor-mediated sensitization to TRAIL-induced apoptosis in childhood malignancies is not associated with upregulation of TRAIL receptor expression, but with potentiated caspase-8 activation. ( Beck, JF; Becker, S; Grauel, D; Palani, CD; Sonnemann, J; Trommer, N; Wittig, S, 2012)
"To potentiate the anticancer activity of siMcl1, the anticancer drug suberoylanilide hydroxamic acid (SAHA) was additionally encapsulated in pTLOL."	1.37	Trilysinoyl oleylamide-based cationic liposomes for systemic co-delivery of siRNA and an anticancer drug. ( Choi, YS; Han, SE; Kim, CW; Kim, K; Kim, YB; Kwon, IC; Lee, HY; Lee, S; Oh, YK; Park, TG; Shim, G; Yu, YH, 2011)
"Lung cancer is the leading cause of cancer death, developing over prolonged periods through genetic and epigenetic changes induced and exacerbated by tobacco exposure."	1.36	Validation of a novel statistical model for assessing the synergy of combined-agent cancer chemoprevention. ( Fujimoto, J; Hong, WK; Kong, M; Lee, JJ; Lotan, R, 2010)
" It has very favorable pharmacokinetic properties after oral dosing in mice, with >4-fold increased bioavailability and 3."	1.36	SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer. ( Bonday, Z; Ethirajulu, K; Goh, KC; Greicius, G; Hart, S; Hentze, H; Hu, CY; Liang, AL; Loh, YK; Novotny-Diermayr, V; Pettersson, S; Sangthongpitag, K; Sausgruber, N; Wang, H; Wood, JM; Wu, X; Yeo, P, 2010)
"Cells from 9 canine cancer cell lines were treated with dimethyl sulfoxide vehicle, OSU-HDAC42, or SAHA, then assays of cell viability were performed."	1.35	Evaluation of the effects of histone deacetylase inhibitors on cells from canine cancer cell lines. ( Chen, CS; Kisseberth, WC; Kulp, SK; London, CA; Murahari, S, 2008)
"HDACis are a group of novel anticancer agents."	1.34	Histone deacetylase inhibitors selectively suppress expression of HDAC7. ( Clarke, C; Dokmanovic, M; Marks, PA; Ngo, L; Parmigiani, RB; Perez, G; Xu, W, 2007)

Research

Studies (159)

Authors

Clinical Trials (9)

Trial Overview

Trial Outcomes

Apparent Terminal Half-Life (t½) of Vorinostat After a Single Oral Dose in a Fasted State

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	38 (23.90)	29.6817
2010's	103 (64.78)	24.3611
2020's	18 (11.32)	2.80

Authors	Studies
Paris, M	1
Porcelloni, M	1
Binaschi, M	1
Fattori, D	1
Wash, PL	1
Hoffman, TZ	1
Wiley, BM	1
Bonnefous, C	1
Smith, ND	1
Sertic, MS	1
Lawrence, CM	1
Symons, KT	1
Nguyen, PM	1
Lustig, KD	1
Guo, X	2
Annable, T	1
Noble, SA	1
Hager, JH	1
Hassig, CA	1
Malecha, JW	1
Cai, X	2
Zhai, HX	2
Wang, J	4
Forrester, J	1
Qu, H	2
Yin, L	2
Lai, CJ	2
Bao, R	2
Qian, C	2
Hou, J	2
Feng, C	1
Li, Z	1
Fang, Q	1
Wang, H	4
Gu, G	1
Shi, Y	1
Liu, P	1
Xu, F	1
Yin, Z	1
Shen, J	1
Wang, P	2
Zhang, Y	7
Feng, J	1
Liu, C	3
Fang, H	3
Xu, W	6
Rajak, H	1
Agarawal, A	1
Parmar, P	1
Thakur, BS	1
Veerasamy, R	1
Sharma, PC	1
Kharya, MD	1
Choi, SE	1
Weerasinghe, SV	1
Pflum, MK	1
Ma, C	2
Jin, K	2
Cao, J	2
Zhang, L	1
Li, X	4
Chou, CJ	1
Wang, X	4
Jia, Y	1
Liang, X	1
Wang, T	3
Sepulveda, M	1
Gonzales, P	1
Gately, S	1
Yang, W	2
Li, L	2
Ji, X	1
Wu, X	2
Su, M	2
Sheng, L	3
Zang, Y	2
Li, J	6
Liu, H	4
Yang, Z	1
Wang, F	1
Niu, T	1
Liu, Z	2
Chen, X	2
Long, C	1
Tang, M	1
Cao, D	1
Xiang, W	1
Yi, Y	1
Ma, L	2
You, J	1
Chen, L	1
Tapadar, S	1
Fathi, S	1
Raji, I	1
Omesiete, W	1
Kornacki, JR	1
Mwakwari, SC	1
Miyata, M	1
Mitsutake, K	1
Li, JD	1
Mrksich, M	1
Oyelere, AK	1
Wen, J	1
Bao, Y	1
Niu, Q	1
Yang, J	5
Fan, Y	1
Jing, Y	1
Zhao, L	1
Liu, D	2
Gong, CJ	1
Gao, AH	1
Zhang, YM	1
Su, MB	1
Chen, F	1
Zhou, YB	1
Li, JY	1
Nan, FJ	1
Cincinelli, R	1
Zwick, V	1
Musso, L	1
Zuco, V	1
De Cesare, M	1
Zunino, F	1
Simoes-Pires, C	1
Nurisso, A	1
Giannini, G	2
Cuendet, M	1
Dallavalle, S	1
Jiao, P	1
Jin, P	1
Li, C	1
Cui, L	1
Dong, L	1
Pan, B	1
Song, W	1
Dong, J	1
Song, L	2
Jin, X	2
Li, F	1
Wan, M	1
Lv, Z	1
Geng, Q	1
Huong, TT	1
Dung, DT	1
Huan, NV	1
Cuong, LV	1
Hai, PT	1
Huong, LT	1
Kim, J	1
Kim, YG	1
Han, SB	1
Nam, NH	1
Li, T	1
Gao, A	1
Chen, C	2
Hou, X	2
Wang, G	1
Pan, W	1
Yang, X	3
Mehndiratta, S	1
Wang, RS	1
Huang, HL	1
Su, CJ	1
Hsu, CM	1
Wu, YW	1
Pan, SL	1
Liou, JP	1
Yuan, Z	1
Sun, Q	1
Li, D	1
Miao, S	1
Chen, S	1
Gao, C	1
Chen, Y	1
Tan, C	1
Jiang, Y	1
Negmeldin, AT	1
Pflum, MKH	1
Zhou, N	1
Yan, Y	1
Dong, G	1
Chen, W	1
Xu, T	1
Zhang, W	1
Rao, Y	1
Miao, C	1
Sheng, C	1
Zhang, Q	1
Li, Y	4
Zhang, B	1
Lu, B	1
Duan, YC	1
Ma, YC	1
Qin, WP	1
Ding, LN	1
Zheng, YC	1
Zhu, YL	1
Zhai, XY	1
Ma, CY	1
Guan, YY	1
Chu-Farseeva, YY	1
Mustafa, N	1
Poulsen, A	1
Tan, EC	1
Yen, JJY	1
Chng, WJ	1
Dymock, BW	2
Sangwan, R	1
Rajan, R	1
Mandal, PK	1
Luan, Y	1
Bernatchez, JA	1
Li, R	1
Song, Y	1
Lim, J	1
Seo, YH	1
Gao, F	1
Zhang, X	1
Xiao, J	1
Wan, Y	3
Yan, C	1
Yan, M	1
Tang, Z	2
Xu, Z	2
Zhao, SJ	1
Liu, Y	3
Liu, T	1
Xiao, Y	1
Xia, C	1
Duan, G	1
Peng, X	1
Sun, Z	1
Kuang, P	1
Chen, J	2
Zhang, J	2
Zhang, M	1
Wei, A	1
Xie, Z	1
Ren, W	1
Duan, W	1
Zhang, Z	1
Shen, A	1
Hu, Y	1
Vaidya, GN	1
Rana, P	1
Venkatesh, A	1
Chatterjee, DR	1
Contractor, D	1
Satpute, DP	1
Nagpure, M	1
Jain, A	1
Kumar, D	1
Long, J	1
Gao, H	1
Rabal, O	1
San José-Enériz, E	1
Agirre, X	1
Sánchez-Arias, JA	1
de Miguel, I	1
Ordoñez, R	1
Garate, L	1
Miranda, E	1
Sáez, E	1
Vilas-Zornoza, A	1
Pineda-Lucena, A	1
Estella, A	1
Zhang, F	1
Wu, W	1
Xu, M	1
Prosper, F	1
Oyarzabal, J	1
Tilekar, K	1
Hess, JD	1
Upadhyay, N	1
Bianco, AL	1
Schweipert, M	1
Laghezza, A	1
Loiodice, F	1
Meyer-Almes, FJ	1
Aguilera, RJ	1
Lavecchia, A	1
C S, R	1
Zhao, H	1
Liu, M	1
Du, J	1
Wu, Q	1
Young, B	1
Wang, Y	6
Davidoff, AM	1
Rankovic, Z	1
Qian, J	1
Meng, C	1
Wu, H	1
Zheng, H	1
Ran, F	1
Liu, GQ	1
Ling, Y	1
Lu, D	1
Wang, C	1
Qu, L	1
Yin, F	1
Li, S	2
Luo, H	1
Liu, X	3
Luo, Z	1
Cui, N	1
Kong, L	1
Yu, Y	1
Wang, B	1
Sun, M	1
Hou, L	1
Wang, S	2
Chen, T	1
Yang, F	1
Ma, Z	1
Sokol, M	3
Gulyaev, I	3
Mollaeva, M	3
Kuznetsov, S	3
Zenin, V	3
Klimenko, M	3
Yabbarov, N	3
Chirkina, M	3
Nikolskaya, E	3
Helmi, YY	1
Papenkordt, N	1
Rennar, G	1
Gbahou, F	1
El-Hady, AK	1
Labani, N	1
Schmidtkunz, K	1
Boettcher, S	1
Jockers, R	1
Abdel-Halim, M	1
Jung, M	2
Zlotos, DP	1
Janku, F	3
Piha-Paul, S	2
Hess, K	2
Broaddus, R	1
Liu, L	1
Shi, N	1
Overman, M	1
Kopetz, S	1
Subbiah, V	3
Naing, A	3
Hong, D	2
Tsimberidou, AM	2
Karp, D	2
Yao, J	1
Fu, S	3
Fischer, F	1
Alves Avelar, LA	1
Patra, S	1
Praharaj, PP	1
Klionsky, DJ	1
Bhutia, SK	1
Nidhyanandan, S	1
Thippeswamy, BS	1
Chandrasekhar, KB	1
Reddy, ND	1
Kulkarni, NM	1
Karthikeyan, K	1
Khan, FR	1
Raghul, J	1
Vijaykanth, G	1
Narayanan, S	1
Xu, S	1
Zhu, X	3
Huang, W	1
Zhou, Y	2
Yan, D	1
Rahmani, S	1
Abdollahi, M	1
Alqinyah, M	1
Hooks, SB	1
Fujii, K	1
Suzuki, N	1
Jimura, N	1
Idogawa, M	1
Kondo, T	1
Iwatsuki, K	1
Kanekura, T	1
Gerelchuluun, A	1
Maeda, J	1
Manabe, E	1
Brents, CA	1
Sakae, T	1
Fujimori, A	1
Chen, DJ	1
Tsuboi, K	1
Kato, TA	1
Cao, F	1
Zwinderman, MRH	1
Dekker, FJ	1
Shi, L	1
Xu, L	1
Guan, Q	1
Zhou, X	2
Zhou, Z	1
Tang, J	1
Zheng, M	1
Shen, Y	1
McGivern, TJP	1
Slator, C	2
Kellett, A	2
Marmion, CJ	1
Jiang, W	1
Li, Q	1
Zhu, Z	1
Wang, Q	2
Dou, J	1
Zhao, Y	1
Lv, W	1
Zhong, F	1
Yao, Y	1
Zhang, G	2
Hao, X	1
Xing, W	1
Yuan, J	1
Bai, J	2
Bolden, JE	1
Shi, W	1
Jankowski, K	1
Kan, CY	1
Cluse, L	1
Martin, BP	1
MacKenzie, KL	1
Smyth, GK	1
Johnstone, RW	3
Wolfson, W	1
Neumann, F	1
Kaddu-Mulindwa, D	1
Widmann, T	1
Preuss, KD	1
Held, G	1
Zwick, C	1
Roemer, K	1
Pfreundschuh, M	1
Kubuschok, B	1
Iwamoto, M	3
Friedman, EJ	2
Sandhu, P	1
Agrawal, NG	2
Rubin, EH	3
Wagner, JA	3
Kolesar, JM	3
Traynor, AM	2
Holen, KD	2
Hoang, T	2
Seo, S	1
Kim, K	3
Alberti, D	3
Espinoza-Delgado, I	5
Wright, JJ	2
Wilding, G	3
Bailey, HH	3
Schelman, WR	3
Deming, DA	1
Ninan, J	1
Eickhoff, J	2
Reid, JM	5
Ames, MM	5
McGovern, RM	4
Marnocha, R	2
Wright, J	1
Attia, S	1
Jiang, Z	1
Thaler, F	1
Dong, M	1
Hu, XS	1
Chen, SS	1
Xing, PY	1
Feng, FY	1
Shi, YK	1
Scott, A	1
Song, J	1
Ewing, R	1
Wang, Z	1
Smith, S	1
Fox, J	1
Mejia, M	1
Ruangpradit, W	1
Saberi, A	1
Kim, S	2
Choi, Y	1
Oh, S	1
Choi, K	1
Hendrickson, EA	1
Takeda, S	1
Muller, M	1
Myung, K	1
Stengel, KR	1
Hiebert, SW	1
Samuni, Y	2
Wink, DA	2
Krishna, MC	2
Mitchell, JB	2
Goldstein, S	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase I Study of Pazopanib and Vorinostat in Patients With Advanced Malignancies[NCT01339871]	Phase 1	152 participants (Actual)	Interventional	2011-04-20	Completed
A Pilot Study to Assess the Safety and Effect on HIV Transcription of Vorinostat in Patients Receiving Suppressive Combination Anti-retroviral Therapy[NCT01365065]	Phase 2	20 participants (Actual)	Interventional	2011-05-31	Active, not recruiting
A Phase I Clinical Study of L-001079038 in Patients With Solid Tumors[NCT00127127]	Phase 1	18 participants (Actual)	Interventional	2005-06-10	Completed
A Randomized, Partially-Blind, Placebo-Controlled, 2-Period Crossover Study to Assess the Effects of a Single Dose of Vorinostat on the QTc Interval in Patients With Advanced Cancer[NCT00632931]	Phase 1	25 participants (Actual)	Interventional	2007-07-31	Completed
A Phase I/II Study of Romidepsin in Combination With Abraxane in Patients With Metastatic Inflammatory Breast Cancer[NCT01938833]	Phase 1/Phase 2	9 participants (Actual)	Interventional	2014-04-30	Terminated (stopped due to Closed by Sponsor)
Phase I/II Intra-patient Dose Escalation Study of Vorinostat in Children With Relapsed Solid Tumor, Lymphoma or Leukemia[NCT01422499]	Phase 1/Phase 2	50 participants (Actual)	Interventional	2012-03-31	Completed
Phase I/II Clinical Trial of Vorinostat in Patients With Recurrent and/or Metastatic Breast Cancer[NCT00416130]	Phase 1/Phase 2	49 participants (Anticipated)	Interventional	2007-01-31	Active, not recruiting
IGHID 11424 - A Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection (The VOR VAX Study)[NCT02707900]	Phase 1	6 participants (Actual)	Interventional	2016-03-31	Terminated (stopped due to Manufacturing of the AGS-004 HIV vaccine by Argos could no longer be provided.)
A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK0683 in Patients With Advanced Cancer[NCT00750178]	Phase 1	30 participants (Actual)	Interventional	2004-11-01	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

t½ is the elimination half-life of study drug. t½ is the time it takes for half of the study drug in the blood plasma to dissipate. (NCT00127127)
Timeframe: Day 1: pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours post-dose

Area Under the Plasma Concentration Time Curve From Hour 0 to Infinity (AUC0-inf) of Vorinostat After a Single Oral Dose in a Fasted State

Intervention	Hours (Mean)
Vorinostat 100 mg FASTED	1.08
Vorinostat 200 mg FASTED	1.83
Vorinostat 400 mg FASTED	1.90
Vorinostat 500 mg FASTED	1.93

AUC0-inf is the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time. (NCT00127127)
Timeframe: Day 1: pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours post-dose

AUC0-inf of Vorinostat After 14 Days of Once-Daily or Twice-Daily Administration

Intervention	μM·hours (Geometric Mean)
Vorinostat 100 mg FASTED	1.20
Vorinostat 200 mg FASTED	2.31
Vorinostat 400 mg FASTED	3.96
Vorinostat 500 mg FASTED	3.47

AUC0-inf is the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time. (NCT00127127)
Timeframe: Day 19: pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours post-dose

AUC0-Inf of Vorinostat After a Single Oral Dose in a Fed State

Intervention	μM·hours (Geometric Mean)
Vorinostat 100 mg Twice-daily	1.33
Vorinostat 200 mg Twice-daily	2.76
Vorinostat 400 mg Once-daily	5.41
Vorinostat 500 mg Once-daily	6.33

AUC0-inf is the area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time. (NCT00127127)
Timeframe: Day 3: pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours post-dose

Cmax of Vorinostat After 14 Days of Once-Daily or Twice-Daily Administration

Intervention	μM·hours (Geometric Mean)
Vorinostat 100 mg FED	0.98
Vorinostat 200 mg FED	2.22
Vorinostat 400 mg FED	4.30
Vorinostat 500 mg FED	5.93

Cmax is a measure of the maximum amount of drug in the plasma after the dose is given. (NCT00127127)
Timeframe: Day 19: pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours post-dose

Cmax of Vorinostat After a Single Oral Dose in a Fed State

Intervention	μM (Geometric Mean)
Vorinostat 100 mg Twice-daily	0.29
Vorinostat 200 mg Twice-daily	0.84
Vorinostat 400 mg Once-daily	0.86
Vorinostat 500 mg Once-daily	1.09

Cmax is a measure of the maximum amount of drug in the plasma after the dose is given. (NCT00127127)
Timeframe: Day 3: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours post-dose

Maximum Concentration (Cmax) of Vorinostat After a Single Oral Dose in a Fasted State

Intervention	μM (Geometric Mean)
Vorinostat 100 mg FED	0.21
Vorinostat 200 mg FED	0.59
Vorinostat 400 mg FED	0.93
Vorinostat 500 mg FED	1.35

Cmax is a measure of the maximum amount of drug in the plasma after the dose is given. (NCT00127127)
Timeframe: Day 1: Pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours post-dose

Number of Participants Who Discontinued Study Treatment Due to an Adverse Event

Intervention	μM (Geometric Mean)
Vorinostat 100 mg FASTED	0.49
Vorinostat 200 mg FASTED	0.77
Vorinostat 400 mg FASTED	1.19
Vorinostat 500 mg FASTED	1.06

An adverse event is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. (NCT00127127)
Timeframe: Up to approximately 4 years

Number of Participants Who Experienced One or More Adverse Events

Intervention	Participants (Count of Participants)
Vorinostat 100 mg	0
Vorinostat 200 mg	1
Vorinostat 400 mg	0
Vorinostat 500 mg	1

Number of Participants With a Dose-Limiting Toxicity (DLT) During Cycle 1

Intervention	Participants (Count of Participants)
Vorinostat 100 mg	4
Vorinostat 200 mg	6
Vorinostat 400 mg	3
Vorinostat 500 mg	6

A DLT was defined as an event considered to be related to study treatment and included: 1) Grade 4 neutropenia refractory to treatments persisting more than 5 days; 2) Grade 3 or more severe neutropenic fever; 3) Grade 3 thrombocytopenia requiring blood transfusions or Grade 4 thrombocytopenia; 4) Grade 4 hemoglobin decrease; 5) Grade 3 or more severe non-hematological toxicities other than anorexia, nausea/vomiting, and fatigue. (For the diarrhea, it was defined as not to use the frequency for the grading. For the alanine aminotransferase [ALT]/aspartate aminotransferase [AST]), it was defined as the case of over 300 IU/L; 6) Grade 3 or more severe anorexia, nausea/vomiting, and fatigue refractory to treatments; and 7) compliance of the study drug, while administrating 14 consecutive days, was less than 50% due to the drug-related adverse experience. (NCT00127127)
Timeframe: Up to 26 days

t½ of Vorinostat After 14 Days of Once-Daily or Twice-Daily Administration

Intervention	Participants (Count of Participants)
Vorinostat 100 mg	0
Vorinostat 200 mg	3
Vorinostat 400 mg	0
Vorinostat 500 mg	2

t½ is the elimination half-life of study drug. t½ is the time it takes for half of the study drug in the blood plasma to dissipate. (NCT00127127)
Timeframe: Day 19: pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours post-dose

t½ of Vorinostat After a Single Oral Dose in a Fed State

Intervention	Hours (Mean)
Vorinostat 100 mg Twice-daily	1.95
Vorinostat 200 mg Twice-daily	1.42
Vorinostat 400 mg Once-daily	1.98
Vorinostat 500 mg Once-daily	1.30

t½ is the elimination half-life of study drug. t½ is the time it takes for half of the study drug in the blood plasma to dissipate. (NCT00127127)
Timeframe: Day 3: pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours post-dose

Time to Maximum Concentration (Tmax) of Vorinostat After a Single Oral Dose in a Fasted State

Intervention	Hours (Mean)
Vorinostat 100 mg FED	1.62
Vorinostat 200 mg FED	1.36
Vorinostat 400 mg FED	2.01
Vorinostat 500 mg FED	1.60

Tmax is a measure of the time to reach the maximum concentration in the plasma after the drug dose. (NCT00127127)
Timeframe: Day 1: pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours post-dose

Tmax of Vorinostat After 14 Days of Once-Daily or Twice-Daily Administration

Intervention	Hours (Mean)
Vorinostat 100 mg FASTED	0.84
Vorinostat 200 mg FASTED	1.59
Vorinostat 400 mg FASTED	2.49
Vorinostat 500 mg FASTED	1.91

Tmax is a measure of the time to reach the maximum concentration in the plasma after the drug dose. (NCT00127127)
Timeframe: Day 19: pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours post-dose

Tmax of Vorinostat After a Single Oral Dose in a Fed State

Intervention	Hours (Mean)
Vorinostat 100 mg Twice-daily	4.66
Vorinostat 200 mg Twice-daily	3.30
Vorinostat 400 mg Once-daily	4.34
Vorinostat 500 mg Once-daily	4.61

Tmax is a measure of the time to reach the maximum concentration in the plasma after the drug dose. (NCT00127127)
Timeframe: Day 3: pre-dose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24 hours post-dose

Change From Baseline in QTcF at 0.5 Hours

Intervention	Hours (Mean)
Vorinostat 100 mg FED	5.66
Vorinostat 200 mg FED	3.00
Vorinostat 400 mg FED	3.53
Vorinostat 500 mg FED	3.17

The Fridericia correction of the QT interval (QTcF) was determined at each time point from five replicate measurements. The change from baseline in QTcF was calculated by subtracting the QTcF value at each timepoint from the QTcF baseline (predose) value. (NCT00632931)
Timeframe: Baseline and 0.5 hours

Change From Baseline in QTcF at 1 Hour

Intervention	milliseconds (Mean)
Vorinostat	1.78
Placebo	-1.22

Fridericia correction of the QT interval (QTcF) was determined at each time point from five replicate measurements. The change from baseline in QTcF was calculated by subtracting the QTcF value at each timepoint from the QTcF baseline (predose) value. (NCT00632931)
Timeframe: Baseline and 1 hour

Change From Baseline in QTcF at 12 Hours

Intervention	milliseconds (Mean)
Vorinostat	0.22
Placebo	-1.23

Change From Baseline in QTcF at 2 Hours

Intervention	milliseconds (Mean)
Vorinostat	1.35
Placebo	-1.31

Change From Baseline in QTcF at 24 Hours

Intervention	milliseconds (Mean)
Vorinostat	1.09
Placebo	-1.98

Change From Baseline in QTcF at 3 Hours

Intervention	milliseconds (Mean)
Vorinostat	1.53
Placebo	-4.89

Change From Baseline in QTcF at 4 Hours

Intervention	milliseconds (Mean)
Vorinostat	1.32
Placebo	-1.52

The Fridericia correction of the QT interval (QTcF) was determined at each time point from five replicate measurements. The placebo-corrected change from baseline in QTcF was calculated by subtracting the QTcF change from baseline for placebo at each timepoint from the QTcF change from baseline for vorinostat at each timepoint. (NCT00632931)
Timeframe: Baseline and 4 hours

Change From Baseline in QTcF at 8 Hours

Article	Year
Histone deacetylase inhibitors: from bench to clinic. Journal of medicinal chemistry, 2008, Mar-27, Volume: 51, Issue:6 Topics: Animals; Antineoplastic Agents; Cell Proliferation; Clinical Trials, Phase I as Topic; Clinical Tria	2008
HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors. European journal of medicinal chemistry, 2018, Oct-05, Volume: 158 Topics: Animals; Antineoplastic Agents; Biological Products; Chemistry Techniques, Synthetic; Drug Discovery	2018
Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy. Journal of medicinal chemistry, 2019, 04-11, Volume: 62, Issue:7 Topics: Binding Sites; Catalytic Domain; Drug Design; Erlotinib Hydrochloride; Histone Deacetylase Inhibitor	2019
Quinolone hybrids and their anti-cancer activities: An overview. European journal of medicinal chemistry, 2019, Mar-01, Volume: 165 Topics: Animals; Antineoplastic Agents; Humans; Neoplasms; Quinolones; Structure-Activity Relationship	2019
Indole: A privileged scaffold for the design of anti-cancer agents. European journal of medicinal chemistry, 2019, Dec-01, Volume: 183 Topics: Antineoplastic Agents; Drug Design; Drug Screening Assays, Antitumor; Humans; Indoles; Myeloid Cell	2019
1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships. European journal of medicinal chemistry, 2019, Dec-01, Volume: 183 Topics: Antineoplastic Agents; Humans; Molecular Structure; Neoplasms; Structure-Activity Relationship; Tria	2019
Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy. Journal of medicinal chemistry, 2020, 09-10, Volume: 63, Issue:17 Topics: Antineoplastic Agents; DNA Damage; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Neo	2020
Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment. European journal of medicinal chemistry, 2020, Dec-15, Volume: 208 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Histone Deacetylase Inhibitors; Histone Deacetylas	2020
Paradigm shift of "classical" HDAC inhibitors to "hybrid" HDAC inhibitors in therapeutic interventions. European journal of medicinal chemistry, 2021, Jan-01, Volume: 209 Topics: Animals; Cardiovascular Diseases; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Humans; Molec	2021
2-Aminothiazole: A privileged scaffold for the discovery of anti-cancer agents. European journal of medicinal chemistry, 2021, Jan-15, Volume: 210 Topics: Animals; Antineoplastic Agents; Drug Design; Drug Discovery; Humans; Neoplasms; Protein Kinase Inhib	2021
Recent Advances with KDM4 Inhibitors and Potential Applications. Journal of medicinal chemistry, 2022, 07-28, Volume: 65, Issue:14 Topics: Enzyme Inhibitors; Histone Demethylases; Humans; Jumonji Domain-Containing Histone Demethylases; Neo	2022
Vorinostat in autophagic cell death: A critical insight into autophagy-mediated, -associated and -dependent cell death for cancer prevention. Drug discovery today, 2022, Volume: 27, Issue:1 Topics: Autophagic Cell Death; Autophagy; Histone Deacetylase Inhibitors; Humans; Neoplasms; Organelle Bioge	2022
Novel treatment opportunities for sulfur mustard-related cancers: genetic and epigenetic perspectives. Archives of toxicology, 2017, Volume: 91, Issue:12 Topics: Antimetabolites, Antineoplastic; Azacitidine; Cancer Vaccines; Carcinogens; Chemical Warfare Agents;	2017
Regulating the regulators: Epigenetic, transcriptional, and post-translational regulation of RGS proteins. Cellular signalling, 2018, Volume: 42 Topics: Animals; Azacitidine; Benzodiazepines; Cardiovascular Diseases; Drugs, Investigational; Epigenesis,	2018
The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors. Molecules (Basel, Switzerland), 2018, Mar-02, Volume: 23, Issue:3 Topics: Antineoplastic Agents; Chemistry Techniques, Synthetic; Depsipeptides; Drug Design; Epigenesis, Gene	2018
Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor. Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:3 Topics: Dose-Response Relationship, Drug; Drug Interactions; Histone Deacetylase Inhibitors; Humans; Hydroxa	2013
Current trends in the development of histone deacetylase inhibitors: a review of recent patent applications. Pharmaceutical patent analyst, 2012, Volume: 1, Issue:1 Topics: Animals; Antineoplastic Agents; Depsipeptides; Drug Approval; Histone Deacetylase Inhibitors; Histon	2012
[Progress in cancer treatment with histone deacetylase inhibitor]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2013, Volume: 35, Issue:7 Topics: Aminopyridines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; C	2013
Regulation of protein stability of DNA methyltransferase 1 by post-translational modifications. Acta biochimica et biophysica Sinica, 2014, Volume: 46, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; DNA (Cytosine-5-)-Methyltransferase 1;	2014
Class I HDACs Affect DNA Replication, Repair, and Chromatin Structure: Implications for Cancer Therapy. Antioxidants & redox signaling, 2015, Jul-01, Volume: 23, Issue:1 Topics: Acetylation; Animals; Chromatin; Depsipeptides; DNA Repair; DNA Replication; Histone Deacetylase Inh	2015
Episensitization: therapeutic tumor resensitization by epigenetic agents: a review and reassessment. Anti-cancer agents in medicinal chemistry, 2014, Volume: 14, Issue:8 Topics: Animals; Antineoplastic Agents; Azacitidine; Azetidines; Benzamides; Decitabine; DNA Modification Me	2014
Histone deacetylase inhibitors: a review on class-I specific inhibition. Mini reviews in medicinal chemistry, 2015, Volume: 15, Issue:9 Topics: Depsipeptides; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Neopl	2015
Common SAR Derived from Multiple QSAR Models on Vorinostat Derivatives Targeting HDACs in Tumor Treatment. Current pharmaceutical design, 2016, Volume: 22, Issue:33 Topics: Histone Deacetylase 1; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acid	2016
Review of bioanalytical assays for the quantitation of various HDAC inhibitors such as vorinostat, belinostat, panobinostat, romidepsin and chidamine. Biomedical chromatography : BMC, 2017, Volume: 31, Issue:1 Topics: Aminopyridines; Animals; Benzamides; Chromatography, High Pressure Liquid; Depsipeptides; Histone De	2017
The Search for Potent, Small-Molecule HDACIs in Cancer Treatment: A Decade After Vorinostat. Medicinal research reviews, 2017, Volume: 37, Issue:6 Topics: Animals; Clinical Trials as Topic; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Neoplas	2017
Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review). International journal of oncology, 2008, Volume: 33, Issue:4 Topics: Antineoplastic Agents; Apoptosis; Chromatin; Depsipeptides; Epigenesis, Genetic; Gene Expression Reg	2008
Development of vorinostat: current applications and future perspectives for cancer therapy. Cancer letters, 2009, Aug-08, Volume: 280, Issue:2 Topics: Acetylation; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinica	2009
New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer. Journal of hematology & oncology, 2009, Jun-01, Volume: 2 Topics: Animals; Antineoplastic Agents; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Gene Ta	2009
Vorinostat in solid and hematologic malignancies. Journal of hematology & oncology, 2009, Jul-27, Volume: 2 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Hem	2009
New patented histone deacetylase inhibitors. Expert opinion on therapeutic patents, 2009, Volume: 19, Issue:12 Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Design; Histone Deacetylase Inhibitor	2009
The role of histone deacetylase inhibitors in the treatment of patients with cutaneous T-cell lymphoma. Clinical lymphoma, myeloma & leukemia, 2010, Volume: 10, Issue:2 Topics: Antineoplastic Agents; Depsipeptides; Hematologic Neoplasms; Histone Deacetylase Inhibitors; Humans;	2010
Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapy. Anti-cancer drugs, 2010, Volume: 21, Issue:9 Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Epigenesis, Genetic; Gene Expression Regulati	2010
Metabolism as a key to histone deacetylase inhibition. Critical reviews in biochemistry and molecular biology, 2011, Volume: 46, Issue:3 Topics: Acetylation; Antineoplastic Agents; Chemoprevention; Chromatin Assembly and Disassembly; Depsipeptid	2011
Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy. Oncogene, 2012, Feb-02, Volume: 31, Issue:5 Topics: Depsipeptides; Histone Deacetylase 1; Histone Deacetylase 2; Histone Deacetylase Inhibitors; Humans;	2012
Targeting histone deacetylases: development of vorinostat for the treatment of cancer. Epigenomics, 2010, Volume: 2, Issue:3 Topics: Acetylation; Animals; Antineoplastic Agents; Gene Expression Regulation, Neoplastic; Histone Deacety	2010
HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunology and cell biology, 2012, Volume: 90, Issue:1 Topics: Acetylation; Antineoplastic Agents; Depsipeptides; Histone Deacetylase Inhibitors; Histone Deacetyla	2012
Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives. Future medicinal chemistry, 2012, Volume: 4, Issue:11 Topics: Antineoplastic Agents; Apoptosis; Depsipeptides; Drug Design; Drug Therapy, Combination; Histone Dea	2012
Suberanilohydroxamic Acid. Aton Pharma. IDrugs : the investigational drugs journal, 2004, Volume: 7, Issue:7 Topics: Animals; Anticarcinogenic Agents; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Hydroxamic Ac	2004
Histone deacetylase inhibitors in programmed cell death and cancer therapy. Cell cycle (Georgetown, Tex.), 2005, Volume: 4, Issue:4 Topics: Antineoplastic Agents; Apoptosis; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Histone	2005
[Histone deacetylase inhibitors as a new generation of anti-cancer agents]. Postepy higieny i medycyny doswiadczalnej (Online), 2005, Mar-11, Volume: 59 Topics: Animals; Antineoplastic Agents; Depsipeptides; Histone Deacetylase Inhibitors; Humans; Hydroxamic Ac	2005
Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nature clinical practice. Oncology, 2005, Volume: 2, Issue:3 Topics: Cell Death; Chromatin; Clinical Trials as Topic; Enzyme Inhibitors; Gene Expression Regulation; Hist	2005
Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nature biotechnology, 2007, Volume: 25, Issue:1 Topics: Animals; Antineoplastic Agents; Cell Proliferation; Clinical Trials as Topic; Dimethyl Sulfoxide; Dr	2007
Histone deacetylase inhibitors in lymphoma and solid malignancies. Expert review of anticancer therapy, 2008, Volume: 8, Issue:3 Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Depsipep	2008
New agents in cancer clinical trials. Oncogene, 2000, Dec-27, Volume: 19, Issue:56 Topics: Antineoplastic Agents; Benzamides; Benzoquinones; Boronic Acids; Bortezomib; Clinical Trials as Topi	2000

Article	Year
Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. Scientific reports, 2020, 02-20, Volume: 10, Issue:1 Topics: Adult; Aged; Angiogenesis Inhibitors; Boron Compounds; Glycine; Humans; Indazoles; Kaplan-Meier Esti	2020
Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes. Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Boronic Acids; Bortezomib; Chromatin Immunop	2013
A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors. Investigational new drugs, 2014, Volume: 32, Issue:2 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Hist	2014
A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies. Investigational new drugs, 2013, Volume: 31, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Female; Hist	2013
Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors. Autophagy, 2014, Volume: 10, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Demograph	2014
Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:5 Topics: Administration, Oral; Adolescent; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chem	2015
Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. Oncotarget, 2016, Oct-11, Volume: 7, Issue:41 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Histone Deacetylase	2016
Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors. Cancer science, 2009, Volume: 100, Issue:9 Topics: Adult; Aged; Enzyme Inhibitors; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Ma	2009
Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker. British journal of cancer, 2009, Oct-06, Volume: 101, Issue:7 Topics: Acetylation; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Doxorub	2009
A single supratherapeutic dose of vorinostat does not prolong the QTc interval in patients with advanced cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Nov-15, Volume: 15, Issue:22 Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Cross-Over Studies; Electrocardiography; Femal	2009
A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors. Investigational new drugs, 2011, Volume: 29, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol	2011
Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Aug-01, Volume: 28, Issue:22 Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy	2010
Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Oct-10, Volume: 28, Issue:29 Topics: Anorexia; Antineoplastic Agents; Area Under Curve; Diarrhea; Dose-Response Relationship, Drug; Fatig	2010
Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Mar-15, Volume: 17, Issue:6 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; CpG	2011
Unexpected high levels of vorinostat when combined with vinorelbine in patients with advanced cancer. Current clinical pharmacology, 2011, Volume: 6, Issue:4 Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Dose-	2011
A phase I trial of vorinostat and bortezomib in children with refractory or recurrent solid tumors: a Children's Oncology Group phase I consortium study (ADVL0916). Pediatric blood & cancer, 2013, Volume: 60, Issue:3 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Child; Child,	2013
Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma or leukemia. Klinische Padiatrie, 2012, Volume: 224, Issue:6 Topics: Administration, Oral; Adolescent; Antineoplastic Agents; Child; Child, Preschool; Dose-Response Rela	2012
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jun-10, Volume: 23, Issue:17 Topics: Administration, Oral; Adult; Aged; Biological Availability; Drug Administration Schedule; Enzyme Inh	2005
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jun-10, Volume: 23, Issue:17 Topics: Administration, Oral; Adult; Aged; Biological Availability; Drug Administration Schedule; Enzyme Inh	2005
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jun-10, Volume: 23, Issue:17 Topics: Administration, Oral; Adult; Aged; Biological Availability; Drug Administration Schedule; Enzyme Inh	2005
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jun-10, Volume: 23, Issue:17 Topics: Administration, Oral; Adult; Aged; Biological Availability; Drug Administration Schedule; Enzyme Inh	2005
A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Dec-01, Volume: 12, Issue:23 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Dietary Fats; Disease Progression; Dose-Respon	2006
Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Jun-15, Volume: 13, Issue:12 Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve	2007

Article	Year
Alpha-mercaptoketone based histone deacetylase inhibitors. Bioorganic & medicinal chemistry letters, 2008, Dec-15, Volume: 18, Issue:24 Topics: Antineoplastic Agents; Chelating Agents; Chemistry, Pharmaceutical; Drug Design; Drug Screening Assa	2008
Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer. Journal of medicinal chemistry, 2010, Mar-11, Volume: 53, Issue:5 Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Growth Processes; Enzyme Inhibitors; ErbB Receptors;	2010
Structure-based optimization of click-based histone deacetylase inhibitors. European journal of medicinal chemistry, 2011, Volume: 46, Issue:8 Topics: Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Cell Proliferation; Click Chemistry; Crystal	2011
Design, synthesis and biological evaluation of tyrosine-based hydroxamic acid analogs as novel histone deacetylases (HDACs) inhibitors. Bioorganic & medicinal chemistry, 2011, Aug-01, Volume: 19, Issue:15 Topics: Antineoplastic Agents; Cell Survival; Drug Design; HeLa Cells; Histone Deacetylase Inhibitors; Histo	2011
2,5-Disubstituted-1,3,4-oxadiazoles/thiadiazole as surface recognition moiety: design and synthesis of novel hydroxamic acid based histone deacetylase inhibitors. Bioorganic & medicinal chemistry letters, 2011, Oct-01, Volume: 21, Issue:19 Topics: Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Cell Proliferation; Drug Design; Drug Eval	2011
The structural requirements of histone deacetylase inhibitors: Suberoylanilide hydroxamic acid analogs modified at the C3 position display isoform selectivity. Bioorganic & medicinal chemistry letters, 2011, Oct-15, Volume: 21, Issue:20 Topics: Antineoplastic Agents; HeLa Cells; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hyd	2011
Novel leucine ureido derivatives as inhibitors of aminopeptidase N (APN). Bioorganic & medicinal chemistry, 2013, Apr-01, Volume: 21, Issue:7 Topics: Animals; Antineoplastic Agents; CD13 Antigens; Cell Line, Tumor; Drug Design; Humans; Inhibitory Con	2013
Design and synthesis of a tetrahydroisoquinoline-based hydroxamate derivative (ZYJ-34v), an oral active histone deacetylase inhibitor with potent antitumor activity. Chemical biology & drug design, 2013, Volume: 82, Issue:2 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; Female; Histone D	2013
Novel β-dicarbonyl derivatives as inhibitors of aminopeptidase N (APN). Bioorganic & medicinal chemistry letters, 2013, Sep-01, Volume: 23, Issue:17 Topics: CD13 Antigens; Humans; Molecular Docking Simulation; Neoplasms; Protease Inhibitors; Zinc	2013
Identification of novel HDAC inhibitors through cell based screening and their evaluation as potential anticancer agents. Bioorganic & medicinal chemistry letters, 2013, Sep-01, Volume: 23, Issue:17 Topics: Animals; Antineoplastic Agents; Benzimidazoles; Cell Line, Tumor; Drug Design; Drug Screening Assays	2013
Design, synthesis and biological evaluation of 4-anilinothieno[2,3-d]pyrimidine-based hydroxamic acid derivatives as novel histone deacetylase inhibitors. Bioorganic & medicinal chemistry, 2014, Nov-01, Volume: 22, Issue:21 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Ant	2014
Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer. Journal of medicinal chemistry, 2016, Feb-25, Volume: 59, Issue:4 Topics: Acetylation; Animals; Antineoplastic Agents; Cell Line, Tumor; Female; Histone Deacetylase 6; Histon	2016
A structure-activity relationship of non-peptide macrocyclic histone deacetylase inhibitors and their anti-proliferative and anti-inflammatory activities. Bioorganic & medicinal chemistry, 2015, Dec-15, Volume: 23, Issue:24 Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Cell Line; Cell Line, Tumor; Cell Prolifer	2015
Identification of N-(6-mercaptohexyl)-3-(4-pyridyl)-1H-pyrazole-5-carboxamide and its disulfide prodrug as potent histone deacetylase inhibitors with in vitro and in vivo anti-tumor efficacy. European journal of medicinal chemistry, 2016, Feb-15, Volume: 109 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Disulfides; Female; Histone Deacetylase Inhibitors	2016
Design, synthesis and biological evaluation of bisthiazole-based trifluoromethyl ketone derivatives as potent HDAC inhibitors with improved cellular efficacy. European journal of medicinal chemistry, 2016, Apr-13, Volume: 112 Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Design; Drug Screening Assays, Antitumor; Halogenation	2016
Biphenyl-4-yl-acrylohydroxamic acids: Identification of a novel indolyl-substituted HDAC inhibitor with antitumor activity. European journal of medicinal chemistry, 2016, Apr-13, Volume: 112 Topics: Antineoplastic Agents; Apoptosis; Biphenyl Compounds; Colonic Neoplasms; Drug Screening Assays, Anti	2016
Design, synthesis and in vitro evaluation of amidoximes as histone deacetylase inhibitors for cancer therapy. Bioorganic & medicinal chemistry letters, 2016, 10-01, Volume: 26, Issue:19 Topics: Histone Deacetylase Inhibitors; Humans; In Vitro Techniques; Neoplasms; Oximes	2016
Novel N-hydroxybenzamides incorporating 2-oxoindoline with unexpected potent histone deacetylase inhibitory effects and antitumor cytotoxicity. Bioorganic chemistry, 2017, Volume: 71 Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Click Chemistry; Crystallography, X-Ray; Drug S	2017
Design, synthesis and biological evaluation of thienopyrimidine hydroxamic acid based derivatives as structurally novel histone deacetylase (HDAC) inhibitors. European journal of medicinal chemistry, 2017, Mar-10, Volume: 128 Topics: Acetylation; Antineoplastic Agents; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumo	2017
Design, synthesis and biological evaluation of quinoline derivatives as HDAC class I inhibitors. European journal of medicinal chemistry, 2017, Jun-16, Volume: 133 Topics: Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Coumaric Acids; Drug Screening Assays,	2017
4-Indolyl-N-hydroxyphenylacrylamides as potent HDAC class I and IIB inhibitors in vitro and in vivo. European journal of medicinal chemistry, 2017, Jul-07, Volume: 134 Topics: Acrylamides; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Histone Deacetyla	2017
Design, synthesis and anticancer potential of NSC-319745 hydroxamic acid derivatives as DNMT and HDAC inhibitors. European journal of medicinal chemistry, 2017, Jul-07, Volume: 134 Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; DNA (Cytosine-5-)-Methyltran	2017
The structural requirements of histone deacetylase inhibitors: SAHA analogs modified at the C5 position display dual HDAC6/8 selectivity. Bioorganic & medicinal chemistry letters, 2017, 08-01, Volume: 27, Issue:15 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Histone Deacetylase 6; Histone Deacetyl	2017
Discovery of a tetrahydroisoquinoline-based HDAC inhibitor with improved plasma stability. Bioorganic & medicinal chemistry, 2017, 09-01, Volume: 25, Issue:17 Topics: Animals; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Drug Evaluation, Preclinical; Drug St	2017
Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors. Journal of medicinal chemistry, 2017, 10-12, Volume: 60, Issue:19 Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Cell Death; Cell Line, Tumor; Drug Discovery;	2017
Design, synthesis and biological evaluation of novel histone deacetylase inhibitors incorporating 4-aminoquinazolinyl systems as capping groups. Bioorganic & medicinal chemistry letters, 2017, 11-01, Volume: 27, Issue:21 Topics: A549 Cells; Animals; Antineoplastic Agents; Binding Sites; Cell Survival; Cells, Cultured; Drug Desi	2017
Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment. European journal of medicinal chemistry, 2017, Nov-10, Volume: 140 Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Enzyme Inhibitors; Histone Deacetylase Inhibitors;	2017
Design and synthesis of potent dual inhibitors of JAK2 and HDAC based on fusing the pharmacophores of XL019 and vorinostat. European journal of medicinal chemistry, 2018, Oct-05, Volume: 158 Topics: Antineoplastic Agents; Apoptosis; Drug Design; HeLa Cells; Histone Deacetylase Inhibitors; Humans; H	2018
A novel class of anthraquinone-based HDAC6 inhibitors. European journal of medicinal chemistry, 2019, Feb-15, Volume: 164 Topics: Acetylation; Anthraquinones; Cell Line, Tumor; Enzyme Assays; Histone Deacetylase 6; Histone Deacety	2019
Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes. European journal of medicinal chemistry, 2021, Jan-01, Volume: 209 Topics: Antineoplastic Agents; Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Drug Design; Drug Discovery	2021
Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with Journal of medicinal chemistry, 2021, 03-25, Volume: 64, Issue:6 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; DNA (Cytosine-5-)-Methyltransf	2021
Thiazolidinedione "Magic Bullets" Simultaneously Targeting PPARγ and HDACs: Design, Synthesis, and Investigations of their Journal of medicinal chemistry, 2021, 05-27, Volume: 64, Issue:10 Topics: Animals; Antineoplastic Agents; Apoptosis; Binding Sites; Cell Cycle Checkpoints; Cell Line, Tumor;	2021
Discovery of DNA-Targeting HDAC Inhibitors with Potent Antitumor Efficacy In Vivo That Trigger Antitumor Immunity. Journal of medicinal chemistry, 2022, 02-24, Volume: 65, Issue:4 Topics: Animals; Antineoplastic Agents; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; DNA; Drug Desi	2022
Redox-Activatable Theranostic Co-Prodrug for Precise Tumor Diagnosis and Selective Combination Chemotherapy. Journal of medicinal chemistry, 2022, 08-11, Volume: 65, Issue:15 Topics: Animals; Cell Line, Tumor; Drug Therapy, Combination; Glutathione; Mice; Nanoparticles; Neoplasms; O	2022
Histone Deacetylase and Enhancer of Zeste Homologue 2 Dual Inhibitors Presenting a Synergistic Effect for the Treatment of Hematological Malignancies. Journal of medicinal chemistry, 2022, 10-13, Volume: 65, Issue:19 Topics: Cell Line, Tumor; Cell Proliferation; Enhancer of Zeste Homolog 2 Protein; Epigenesis, Genetic; Hema	2022
Lysosomal activable Vorinostat carrier-prodrug self-assembling with BPQDs enables photothermal oncotherapy to reverse tumor thermotolerance and metastasis. International journal of pharmaceutics, 2022, Apr-05, Volume: 617 Topics: Cell Line, Tumor; Humans; Lysosomes; Neoplasms; Prodrugs; Thermotolerance; Vorinostat	2022
Box-Behnken assisted development and validation of high-performance liquid chromatography method for the simultaneous determination of doxorubicin and vorinostat in polymeric nanoparticles. Journal of separation science, 2023, Volume: 46, Issue:3 Topics: Chromatography, High Pressure Liquid; Doxorubicin; Histone Deacetylase Inhibitors; Humans; Nanoparti	2023
Box-Behnken assisted development and validation of high-performance liquid chromatography method for the simultaneous determination of doxorubicin and vorinostat in polymeric nanoparticles. Journal of separation science, 2023, Volume: 46, Issue:3 Topics: Chromatography, High Pressure Liquid; Doxorubicin; Histone Deacetylase Inhibitors; Humans; Nanoparti	2023
Box-Behnken assisted development and validation of high-performance liquid chromatography method for the simultaneous determination of doxorubicin and vorinostat in polymeric nanoparticles. Journal of separation science, 2023, Volume: 46, Issue:3 Topics: Chromatography, High Pressure Liquid; Doxorubicin; Histone Deacetylase Inhibitors; Humans; Nanoparti	2023
Box-Behnken assisted development and validation of high-performance liquid chromatography method for the simultaneous determination of doxorubicin and vorinostat in polymeric nanoparticles. Journal of separation science, 2023, Volume: 46, Issue:3 Topics: Chromatography, High Pressure Liquid; Doxorubicin; Histone Deacetylase Inhibitors; Humans; Nanoparti	2023
Box-Behnken assisted development and validation of high-performance liquid chromatography method for the simultaneous determination of doxorubicin and vorinostat in polymeric nanoparticles. Journal of separation science, 2023, Volume: 46, Issue:3 Topics: Chromatography, High Pressure Liquid; Doxorubicin; Histone Deacetylase Inhibitors; Humans; Nanoparti	2023
Box-Behnken assisted development and validation of high-performance liquid chromatography method for the simultaneous determination of doxorubicin and vorinostat in polymeric nanoparticles. Journal of separation science, 2023, Volume: 46, Issue:3 Topics: Chromatography, High Pressure Liquid; Doxorubicin; Histone Deacetylase Inhibitors; Humans; Nanoparti	2023
Box-Behnken assisted development and validation of high-performance liquid chromatography method for the simultaneous determination of doxorubicin and vorinostat in polymeric nanoparticles. Journal of separation science, 2023, Volume: 46, Issue:3 Topics: Chromatography, High Pressure Liquid; Doxorubicin; Histone Deacetylase Inhibitors; Humans; Nanoparti	2023
Box-Behnken assisted development and validation of high-performance liquid chromatography method for the simultaneous determination of doxorubicin and vorinostat in polymeric nanoparticles. Journal of separation science, 2023, Volume: 46, Issue:3 Topics: Chromatography, High Pressure Liquid; Doxorubicin; Histone Deacetylase Inhibitors; Humans; Nanoparti	2023
Box-Behnken assisted development and validation of high-performance liquid chromatography method for the simultaneous determination of doxorubicin and vorinostat in polymeric nanoparticles. Journal of separation science, 2023, Volume: 46, Issue:3 Topics: Chromatography, High Pressure Liquid; Doxorubicin; Histone Deacetylase Inhibitors; Humans; Nanoparti	2023
Melatonin-vorinostat hybrid ligands show higher histone deacetylase and cancer cell growth inhibition than vorinostat. Archiv der Pharmazie, 2023, Volume: 356, Issue:9 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Histone Deacetylase 1; Histone Deacetyl	2023
A short overview of resistance to approved histone deacetylase inhibitors. Future medicinal chemistry, 2021, Volume: 13, Issue:14 Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Drug Resistance, Neoplasm; Histone Deacetyl	2021
Enhanced anticancer efficacy of histone deacetyl inhibitor, suberoylanilide hydroxamic acid, in combination with a phosphodiesterase inhibitor, pentoxifylline, in human cancer cell lines and in-vivo tumor xenografts. Anti-cancer drugs, 2017, Volume: 28, Issue:9 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Growth Processe	2017
Supramolecular cisplatin-vorinostat nanodrug for overcoming drug resistance in cancer synergistic therapy. Journal of controlled release : official journal of the Controlled Release Society, 2017, Nov-28, Volume: 266 Topics: A549 Cells; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Sur	2017
HSP72 functionally inhibits the anti-neoplastic effects of HDAC inhibitors. Journal of dermatological science, 2018, Volume: 90, Issue:1 Topics: Acetylation; Apoptosis; Benzhydryl Compounds; Drug Resistance, Neoplasm; Gene Expression Regulation,	2018
Histone Deacetylase Inhibitor Induced Radiation Sensitization Effects on Human Cancer Cells after Photon and Hadron Radiation Exposure. International journal of molecular sciences, 2018, Feb-07, Volume: 19, Issue:2 Topics: A549 Cells; Biomarkers, Tumor; Cell Cycle; Cell Proliferation; Cell Survival; DNA Breaks, Double-Str	2018
Light-Trigerred Cellular Epigenetic Molecule Release To Reverse Tumor Multidrug Resistance. Bioconjugate chemistry, 2018, 04-18, Volume: 29, Issue:4 Topics: Antineoplastic Agents; Apoptosis; Delayed-Action Preparations; Drug Resistance, Multiple; Drug Resis	2018
SAHA (vorinostat) facilitates functional polymer-based gene transfection via upregulation of ROS and synergizes with TRAIL gene delivery for cancer therapy. Journal of drug targeting, 2019, Volume: 27, Issue:3 Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Combined Modality Therapy; Gene Transfer Tech	2019
Innovative DNA-Targeted Metallo-prodrug Strategy Combining Histone Deacetylase Inhibition with Oxidative Stress. Molecular pharmaceutics, 2018, 11-05, Volume: 15, Issue:11 Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Copper; DNA;	2018
Cancer Chemoradiotherapy Duo: Nano-Enabled Targeting of DNA Lesion Formation and DNA Damage Response. ACS applied materials & interfaces, 2018, Oct-24, Volume: 10, Issue:42 Topics: Animals; Antineoplastic Agents; Cell Cycle Checkpoints; Cell Line, Tumor; Chemoradiotherapy; Cisplat	2018
Cotargeting the JAK/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasms. Investigational new drugs, 2020, Volume: 38, Issue:3 Topics: Animals; Apoptosis; Cell Cycle Checkpoints; Cell Proliferation; Drug Synergism; Histone Deacetylases	2020
HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses. Cell death & disease, 2013, Feb-28, Volume: 4 Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Cell Line; Depsipeptides; Epigenomics; Gene Express	2013
Epigenetic cancer therapies emerge out of the lab into the limelight. Chemistry & biology, 2013, Apr-18, Volume: 20, Issue:4 Topics: Antineoplastic Agents; Azacitidine; Benzamides; Clinical Trials as Topic; Depsipeptides; Drug Resist	2013
EBV-transformed lymphoblastoid cell lines as vaccines against cancer testis antigen-positive tumors. Cancer immunology, immunotherapy : CII, 2013, Volume: 62, Issue:7 Topics: Antigen-Presenting Cells; Antigens, Neoplasm; Azacitidine; B-Lymphocytes; Cancer Vaccines; CD4-Posit	2013
Histone deacetylase inhibitors selectively target homology dependent DNA repair defective cells and elevate non-homologous endjoining activity. PloS one, 2014, Volume: 9, Issue:1 Topics: Animals; Antigens, Nuclear; B-Lymphocytes; Blotting, Western; Cell Survival; Cells, Cultured; Chicke	2014
Suberoylanilide hydroxamic acid radiosensitizes tumor hypoxic cells in vitro through the oxidation of nitroxyl to nitric oxide. Free radical biology & medicine, 2014, Volume: 73 Topics: Antioxidants; Cell Hypoxia; Cell Line, Tumor; Cyclic N-Oxides; Enzyme Inhibitors; G1 Phase Cell Cycl	2014
The NKG2D ligand ULBP2 is specifically regulated through an invariant chain-dependent endosomal pathway. Journal of immunology (Baltimore, Md. : 1950), 2014, Aug-15, Volume: 193, Issue:4 Topics: Antigens, Differentiation, B-Lymphocyte; Antigens, Surface; Biological Transport; Carbazoles; CD4-Po	2014
Biocompatibility and biodistribution of suberoylanilide hydroxamic acid loaded poly (DL-lactide-co-glycolide) nanoparticles for targeted drug delivery in cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2014, Volume: 68, Issue:7 Topics: Animals; Antineoplastic Agents; Biocompatible Materials; Cell Line, Tumor; Drug Delivery Systems; Hi	2014
Systematic analysis of time-series gene expression data on tumor cell-selective apoptotic responses to HDAC inhibitors. Computational and mathematical methods in medicine, 2014, Volume: 2014 Topics: Algorithms; Apoptosis; Cell Cycle; Cluster Analysis; DNA Damage; Gene Expression Profiling; Gene Exp	2014
Nanoparticle formulations of histone deacetylase inhibitors for effective chemoradiotherapy in solid tumors. Biomaterials, 2015, Volume: 51 Topics: Animals; Cell Line, Tumor; Chemistry, Pharmaceutical; Chemoradiotherapy; Histone Deacetylase Inhibit	2015
DNA methylation and histone modifications regulate SOX11 expression in lymphoid and solid cancer cells. BMC cancer, 2015, Apr-12, Volume: 15 Topics: Cell Line, Tumor; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Hist	2015
4-(1-Ethyl-4-anisyl-imidazol-5-yl)-N-hydroxycinnamide - A new pleiotropic HDAC inhibitor targeting cancer cell signalling and cytoskeletal organisation. Experimental cell research, 2015, Aug-15, Volume: 336, Issue:2 Topics: Animals; Antineoplastic Agents; Apoptosis; beta Catenin; Cell Line, Tumor; Cell Movement; Cell Proli	2015
Epigenetic Alterations in Fanconi Anaemia: Role in Pathophysiology and Therapeutic Potential. PloS one, 2015, Volume: 10, Issue:10 Topics: Adolescent; Adult; Child; Child, Preschool; Chromatin; Chromosomal Instability; Computational Biolog	2015
Oncogenic K-ras confers SAHA resistance by up-regulating HDAC6 and c-myc expression. Oncotarget, 2016, Mar-01, Volume: 7, Issue:9 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cell Line, Tumor; Chromones; Dru	2016
Pharmacological Analysis of Vorinostat Analogues as Potential Anti-tumor Agents Targeting Human Histone Deacetylases: an Epigenetic Treatment Stratagem for Cancers. Asian Pacific journal of cancer prevention : APJCP, 2016, Volume: 17, Issue:3 Topics: Acetylation; Antineoplastic Agents; Apoptosis; Cell Proliferation; Drug Discovery; Drug Screening As	2016
HDAC Inhibitors. Methods in molecular biology (Clifton, N.J.), 2016, Volume: 1436 Topics: Acetylation; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumo	2016
Triggering autophagic cell death with a di-manganese(II) developmental therapeutic. Redox biology, 2017, Volume: 12 Topics: Antineoplastic Agents; Autophagosomes; Autophagy; Cell Line, Tumor; Cell Survival; Circular Dichrois	2017
No adverse safety or virological changes 2 years following vorinostat in HIV-infected individuals on antiretroviral therapy. AIDS (London, England), 2017, 05-15, Volume: 31, Issue:8 Topics: Anti-Retroviral Agents; Antineoplastic Agents; CD4 Lymphocyte Count; CD4-CD8 Ratio; Drug Interaction	2017
In vitro plasma stability, permeability and solubility of mercaptoacetamide histone deacetylase inhibitors. International journal of pharmaceutics, 2008, Sep-01, Volume: 361, Issue:1-2 Topics: Acetamides; Animals; Antineoplastic Agents; Caco-2 Cells; Chemistry, Pharmaceutical; Drug Stability;	2008
Evaluation of the effects of histone deacetylase inhibitors on cells from canine cancer cell lines. American journal of veterinary research, 2008, Volume: 69, Issue:7 Topics: Acetylation; Animals; Apoptosis; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Survival; DNA	2008
Histone deacetylase inhibitors promote apoptosis and senescence in human mesenchymal stem cells. Stem cells and development, 2009, Volume: 18, Issue:4 Topics: Apoptosis; Benzamides; Cell Cycle; Cellular Senescence; Enzyme Inhibitors; Histone Deacetylase Inhib	2009
Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Sep-01, Volume: 14, Issue:17 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; CASP8 and FADD-Like Ap	2008
HDAC inhibitors: magic bullets, dirty drugs or just another targeted therapy. Cancer letters, 2009, Aug-08, Volume: 280, Issue:2 Topics: Antineoplastic Agents; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Histone Deacetylases; Hu	2009
The inhibitors of histone deacetylase suberoylanilide hydroxamate and trichostatin A release nitric oxide upon oxidation. Free radical biology & medicine, 2009, Aug-15, Volume: 47, Issue:4 Topics: Animals; Antineoplastic Agents; Antioxidants; Cells, Cultured; Cricetinae; Electron Spin Resonance S	2009
American Association for Cancer Research 100th Annual Meeting. The Lancet. Oncology, 2009, Volume: 10, Issue:6 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A	2009
Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8. Oncogene, 2009, Sep-03, Volume: 28, Issue:35 Topics: Benzamides; Caspase 8; Cell Line, Tumor; Cell Survival; Cerebellar Neoplasms; Drug Combinations; Dru	2009
SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer. Molecular cancer therapeutics, 2010, Volume: 9, Issue:3 Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Colorectal Neoplasms;	2010
Validation of a novel statistical model for assessing the synergy of combined-agent cancer chemoprevention. Cancer prevention research (Philadelphia, Pa.), 2010, Volume: 3, Issue:8 Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Line, Tumor; Cell Prol	2010
Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression. Investigational new drugs, 2012, Volume: 30, Issue:1 Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blotting, Western; Butyrate	2012
Synergistic killing effect between vorinostat and target of CD146 in malignant cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Nov-01, Volume: 16, Issue:21 Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; CD146 Antigen; Cell	2010
Combination of sapacitabine and HDAC inhibitors stimulates cell death in AML and other tumour types. British journal of cancer, 2010, Oct-26, Volume: 103, Issue:9 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Cell Death; Cell Line,	2010
Trilysinoyl oleylamide-based cationic liposomes for systemic co-delivery of siRNA and an anticancer drug. Journal of controlled release : official journal of the Controlled Release Society, 2011, Oct-10, Volume: 155, Issue:1 Topics: Animals; Antineoplastic Agents; Cations; Cell Line; Female; Gene Silencing; Humans; Hydroxamic Acids	2011
HDAC inhibitors downregulate MRP2 expression in multidrug resistant cancer cells: implication for chemosensitization. International journal of oncology, 2011, Volume: 38, Issue:3 Topics: Antineoplastic Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Down-Regulation; Drug Eva	2011
Histone deacetylase inhibitor-mediated sensitization to TRAIL-induced apoptosis in childhood malignancies is not associated with upregulation of TRAIL receptor expression, but with potentiated caspase-8 activation. Cancer biology & therapy, 2012, Volume: 13, Issue:6 Topics: Apoptosis; Bone Neoplasms; Caspase 8; Cell Line, Tumor; Enzyme Activation; Histone Deacetylase Inhib	2012
Tumor vasculature targeting following co-delivery of heparin-taurocholate conjugate and suberoylanilide hydroxamic acid using cationic nanolipoplex. Biomaterials, 2012, Volume: 33, Issue:17 Topics: Animals; Antineoplastic Agents; Cations; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems	2012
Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling. Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Aug-01, Volume: 18, Issue:15 Topics: Animals; Apoptosis; Blotting, Western; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation;	2012
Cancer research: Open ambition. Nature, 2012, Aug-09, Volume: 488, Issue:7410 Topics: Adult; Animals; Azepines; Benzodiazepines; Cell Cycle Proteins; Child; Epigenesis, Genetic; Histone	2012
Curbing autophagy and histone deacetylases to kill cancer cells. Autophagy, 2012, Volume: 8, Issue:10 Topics: Animals; Autophagy; Cell Line, Tumor; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans;	2012
The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proceedings of the National Academy of Sciences of the United States of America, 2002, Sep-03, Volume: 99, Issue:18 Topics: Apoptosis; Base Sequence; Carrier Proteins; Cell Division; Cloning, Molecular; DNA Primers; Down-Reg	2002
Microarray profiling of the effects of histone deacetylase inhibitors on gene expression in cancer cell lines. International journal of oncology, 2004, Volume: 24, Issue:4 Topics: Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Enzyme Inhibitors; Gene Expression Profiling; Gene	2004
Silent advances. Environmental health perspectives, 2004, Volume: 112, Issue:4 Topics: Antineoplastic Agents; Gene Expression Regulation; Gene Silencing; Histone Deacetylases; Humans; Hyd	2004
Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2004, Dec-28, Volume: 101, Issue:52 Topics: Animals; Apoptosis; Apoptotic Protease-Activating Factor 1; Autophagy; bcl-X Protein; Butyrates; Cas	2004
Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proceedings of the National Academy of Sciences of the United States of America, 2005, Jan-18, Volume: 102, Issue:3 Topics: Apoptosis; Benzamides; Caspases; Cell Line, Transformed; Drug Resistance, Neoplasm; Enzyme Inhibitor	2005
Histone deacetylase inhibitors sit at crossroads of diet, aging, cancer. Journal of the National Cancer Institute, 2006, Mar-15, Volume: 98, Issue:6 Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents; Clinical Trials as Topic; Enzyme Inhibitors	2006
Epigenetic cancer therapy makes headway. Journal of the National Cancer Institute, 2006, Oct-18, Volume: 98, Issue:20 Topics: Acetylation; Animals; Antineoplastic Agents; Azacitidine; Decitabine; DNA Methylation; Epigenesis, G	2006
HDAC inhibitors overcome first hurdle. Nature biotechnology, 2007, Volume: 25, Issue:1 Topics: Clinical Trials as Topic; Drug Approval; Heart Diseases; Histone Deacetylase Inhibitors; Humans; Hyd	2007
Histone deacetylase inhibitors selectively suppress expression of HDAC7. Molecular cancer therapeutics, 2007, Volume: 6, Issue:9 Topics: Acetylation; Blotting, Northern; Blotting, Western; Cell Transformation, Neoplastic; Cyclin-Dependen	2007
Optimization of activity-based probes for proteomic profiling of histone deacetylase complexes. Journal of the American Chemical Society, 2008, Feb-20, Volume: 130, Issue:7 Topics: Benzophenones; Cell Line, Tumor; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Histone Deacetyl	2008

vorinostat and Benign Neoplasms